Note: Descriptions are shown in the official language in which they were submitted.
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
ANTI-MICROBIAL COATING AND METHOD TO FORM SAME
Field Of The Invention
[0001] Embodiments generally relate an anti-microbial coating
composition, and
a method using that coating composition. In certain embodiments, the coating
composition comprises a photocatalyst. In certain embodiments, the
photocatalyst
comprises a titanyl-oxide moiety. In certain embodiments, the coating
composition
comprises a silane.
Brief Description Of The Drawings
[0002] The invention will be better understood from a reading of the
following
detailed description taken in conjunction with the drawings in which like
reference
designators are used to designate like elements, and in which:
[0003] FIG. 1 graphically shows the number of hospital acquired C-
difficile
infections in the Glendale Memorial Hospital ICU from January 2012 through
February 2014;
[0004] FIG. 2 graphically shows the number of hospital acquired C-
difficile
infections at the Glendale Memorial Hospital (excluding ICU) from January 2012
through February 2014;
[0005] FIG. 3 shows anti-microbial efficacy data zero (0) hours after
inoculation
of the treated test coupons;
[0006] FIG. 4 recite anti-microbial efficacy data four (4) hours after
inoculation
of the treated test coupon which includes data for ABS-G2020 AND ABS-G2030
treated Formica coupons;
[0007] FIG. 5 recite anti-microbial efficacy data four (4) hours after
inoculation
of the treated test coupon which includes data for ABS-G2020 AND ABS-G2030
treated stain less steel coupons;
[0008] FIG. 6 recite surface time-kill study evaluating two coating
formulations
against murine norovirus (6) hours contact time data;
1
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[0009] FIG. 7 recites CFU/mL data for each of the three coating
formulations,
wherein each formulation did not include one or more titanium-oxide moieties;
[00010] FIG. 8 recites Log Reduction data for the three formulations
evaluated,
wherein each formulation did not include one or more titanium-oxide moieties;
[00011] FIG. 9 recites Percent Reduction data for the three formulations
utilized,
wherein each formulation did not include one or more titanium-oxide moieties;
[00012] FIG. 10 recite anti-microbial efficacy data for certain
electrostatic spray
embodiments;
[00013] FIG. 11 recite anti-microbial efficacy data for certain
electrostatic spray
embodiments;
[00014] FIG. 12 recite anti-microbial efficacy data for certain
electrostatic spray
embodiments;
[00015] FIG. 13 recite anti-microbial efficacy data for certain non-
electrostatic
spray embodiments;
[00016] FIG. 14 recite anti-microbial efficacy data for certain non-
electrostatic
spray embodiments; and
[00017] FIG. 15 recite anti-microbial efficacy data for certain non-
electrostatic
spray embodiments.
Detailed Description Of The Preferred Embodiments
[00018] This invention is described in preferred embodiments in the
following
description with reference to the Figures, in which like numbers represent the
same or
similar elements. Reference throughout this specification to "one embodiment,"
"an
embodiment," or similar language means that a particular feature, structure,
or
characteristic described in connection with the embodiment is included in at
least one
embodiment of the present invention. Thus, appearances of the phrases "in one
embodiment," "in an embodiment," and similar language throughout this
specification
may, but do not necessarily, all refer to the same embodiment.
2
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00019] The described features, structures, or characteristics of the
invention may
be combined in any suitable manner in one or more embodiments. In the
following
description, numerous specific details are recited to provide a thorough
understanding
of embodiments of the invention. One skilled in the relevant art will
recognize,
however, that the invention may be practiced without one or more of the
specific
details, or with other methods, components, materials, and so forth. In other
instances, well-known structures, materials, or operations are not shown or
described
in detail to avoid obscuring aspects of the invention.
[00020] In certain embodiments of Inventors' composition and method, a
coating is
formed on a surface, where that coating comprises a plurality of silicon -
oxygen
bonds. In certain embodiments of Inventors' composition and method, a coating
is
formed on a surface, where that coating comprises a plurality of titanium -
oxygen
bonds in combination with a plurality of silicon-oxygen bonds.
[00021] In certain embodiments, a coating comprising a plurality of
titanyl-oxide
bonds in combination with a plurality of silicon-oxygen bonds is formed by
disposing
on a surface a silane in combination with one or more compounds comprising one
or
more titanyl-oxygen bonds. In certain embodiments, a coating comprising a
plurality
of titanyl-oxide bonds in combination with a plurality of silicon-oxygen bonds
is
formed by first disposing one or more compounds comprising one or more titanyl-
oxygen bonds on the surface, and by disposing a silane onto the surface and
over the
one or more compounds comprising one or more titanyl-oxygen bonds. In certain
embodiments, a coating comprising a plurality of titanyl-oxide bonds in
combination
with a plurality of silicon-oxygen bonds is formed by simultaneously disposing
one or
more compounds comprising one or more titanyl-oxygen bonds and a silane onto
the
surface.
[00022] In certain embodiments, Inventors silane comprises compound I.
3
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
R4
Sk
R3" \ R1
R2
1
[00023] In certain embodiments, RI is selected from the group consisting
of OH
and 0-Alkyl. In certain embodiments, R2 is selected from the group consisting
of OH
and 0-Alkyl. In certain embodiments, R3 is selected from the group consisting
of OH
and 0-Alkyl. In certain embodiments, R4 is selected from the group consisting
of
OH, 0-Alkyl, Alkyl, substituted Alkyl including y-chloro-propyl, y-amino-
propyl,
and quarternary ammonium salt-substituted Alkyl.
[00024] In certain embodiments, Inventors' silane comprises a trihydroxy
silane 2.
R4
H. Si, ,H
2
[00025] In certain embodiments, Inventors' silane comprises a silanetriol
2,
wherein R4 is alkyl. In other embodiments, Inventors' silane comprises a
silanetriol
2, wherein R4 is alkyl with an amino moiety. In yet other embodiments,
Inventors'
silane comprises a silanetriol 2, wherein R4 is alkyl with a chlorine
substituent. In
still other embodiments, Inventors' silane comprises a silanetriol 2, wherein
R4 is
alkyl with a quarternary ammonium group.
4
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00026] A silsesquioxane is an organosilicon compound 3 where Si
represents the
element silicon and 0 represents the element oxygen.
"141 Si
C)
0
0
r
Si
;
=
3
In certain embodiments, after application of Inventors' silane 1 or 2 to
either a hard
surface, i.e. wall, door, table, and the like, or a soft surface, i.e.
bedding, draperies,
furniture cushions, and the like, a resulting coating disposed on the hard
surface soft
surface comprising a plurality of silsesquioxane structures. In certain
embodiments,
after application of Inventors' silane 1 or 2 in combination with one or more
compounds comprising a titanyl-oxygen moiety, to either a hard surface, i.e.
wall,
door, table, and the like, or a soft surface, i.e. bedding, draperies,
furniture cushions,
and the like, a resulting coating disposed on the hard surface / soft surface
comprises a
plurality of silsesquioxane structures 3 in combination with plurality of
titanyl-oxide
structures.
[00027] Oxidation is a loss of electrons or an increase in oxidation state
by a
molecule, atom or ion. Substances that have the ability to oxidize other
substances
are said to be oxidative or oxidizing and are known as oxidizing agents,
oxidants, or
oxidizers. Put another way, the oxidant removes electrons from another
substance,
and is thus itself reduced. And, because it "accepts" electrons, it is also
called an
electron acceptor.
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00028] In chemistry, photocatalysis is the acceleration of a
photoreaction in the
presence of a catalyst. In catalyzed photolysis, light is absorbed by an
adsorbed
substrate. In photogenerated catalysis, the photocatalytic activity (PCA)
depends on
the ability of the catalyst to create electron¨hole pairs, which generate free
radicals
(hydroxyl radicals: .0H) able to undergo secondary reactions. Its
comprehension has
been made possible ever since the discovery of water electrolysis by means of
the
titanium dioxide.
[00029] Certain titanyl-oxide morphologies exhibit photocatalytic
characteristics
when exposed to Ultra Violet (UV) light. When exposed to UV light, Inventors'
Titanyl-Oxide Moieties create electron-hole pairs which generate free radical
(e.g.,
hydroxyl radicals). The degree of photocatalytic strength varies depending on
the
type of titanyl-oxide, for example anatase titanium oxide (particle size of
about 5 to
30 nanometers) is a stronger photocatalyst than rutile titanium oxide
(particle size of
about 0.5 to 1 microns).
[00030] In certain embodiments of Inventors' composition and method, a
coating is
formed on a surface, where that coating comprises a plurality of titanyl-oxide
bonds,
where that coating is formed by disposing Inventors' Titanyl-Oxide Moieties
onto a
target surface.
[00031] In certain embodiments of Inventors' composition and method, a
coating is
formed on a surface, where that coating comprises a plurality of silicon-
oxygen
bonds, where that coating is formed by disposing Inventors' silane 1 onto the
surface.
[00032] In certain embodiments of Inventors' composition and method, a
coating is
formed on a surface, where that coating comprises a plurality of titanyl-oxide
bonds,
where that coating is formed by disposing on the surface a mixture of
Peroxotitanium
acid solution and Peroxo-modified anatase sol (collectively "Titanyl-Oxide
Moieties").
6
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
[00033] In certain embodiments, Inventors' Titanyl-Oxide Moieties
comprises up
to about a total of one weight percent loading of the mixture of
Peroxotitanium acid
solution and Peroxo-modified anatase sol. In certain embodiments, Inventors'
Titanyl-Oxide Moieties comprises about 0.5 weight percent Peroxotitanium acid
solution in combination with about 0.5 weight percent Peroxo-modified anatase
sol.
[00034] A method to prepare both Peroxotitanium acid solution and Peroxo-
modified anatase sol is disclosed in Journal of Sol-Gel Science and
Technology,
September 2001, Volume 22, Issue 1-2, pp 33-40. This publication discloses,
inter
alia, Reaction Scheme 1, shown immediately hereinbelow, which summarizes the
synthetic procedure for both Peroxotitanium acid solution and Peroxo-modified
anatase sol.
REACTION SCHEME 1
.. .
: TiC14 solution ..]
ItiO2 .---"*" .11_ 1,484011
,....: .
V
Ery,x. otikardurn ,complirt cal.ution. I pH>I0
,1 ..-.
L__:..:...._. .
PrecipitateL or elroxotitrawlm hydrate
.. . . .
.....
Washing and deionization
Y
Poroxatitanium hydrate I -
suspension
H202 --,,,..-0,-
,1, Heating at 100tt
Ptraxotitaniurn acid Peroxo-mcdified
solution . iln4tat:,4 Sof
= ¨ . ====
7
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00035] in the following examples, reference is made to coatings ABS-
G2015,
ABS-G2020, and ABS-G2030. Coating formulation ABS-G2015 comprises a
silicone-containing compound having structure V:
CH3
+1
C CI
CH318
,Si
0 \O
I 01
I H
V
[00036] Coating formulation ABS-G2015 further comprises the Titanyl-
Oxide
Moieties. The order of deposition onto a surface is not critical. In certain
embodiments, the silicone-containing compound is first disposed on a surface,
and the
Titanyl-Oxide Moieties are disposed over that silicone-containing compound. In
other embodiments, the Titanyl-Oxide Moieties are first disposed on a surface,
and
the silicone-containing compound is disposed over that Titanyl-Oxide Moieties -
treated surface. In yet other embodiments, the Titanyl-Oxide Moieties and the
silicone-containing compound are first pre-mixed, and the resulting mixture is
disposed on the surface of the substrate.
8
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00037] Coating formulation ABS-G2020 comprises a silicone-containing
compound having structure VI:
CI
Si
0 \ 0
I 01
H H
VI
[00038] Coating formulation ABS-G2020 further comprises the Titanyl-
oxide
Moieties. The order of deposition onto a surface is not critical. In certain
embodiments, the silicone-containing compound is first disposed on a surface,
and the
Titanyl-oxide Moieties are disposed over that silicone-containing compound. In
other
embodiments, the Titanyl-oxide Moieties are first disposed on a surface, and
the
silicone-containing compound is disposed over that Titanyl-oxide Moieties-
treated
surface. In yet other embodiments, the Titanyl-oxi de Moieties and the
silicone-
containing compound are first pre-mixed, and the resulting mixture is disposed
on the
surface of the substrate.
[00039] Coating foi mutation ABS-G2030 comprises a silicone-containing
compound having structure VII:
9
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
NH2
Si
I 0 I
H H
VII
[00040] Coating formulation ABS-G2030 further comprises the Titanyl-Oxide
Moieties. The order of deposition onto a surface is not critical. In certain
embodiments, the silicone-containing compound is first disposed on a surface,
and the
Titanyl-Oxide Moieties are disposed over that silicone-containing compound. In
other embodiments, the Titanyl-Oxide Moieties are first disposed on a surface,
and
the silicone-containing compound is disposed over that Titanyl-Oxide Moieties-
treated surface. In yet other embodiments, the Titanyl-Oxide Moieties and the
silicone-containing compound are first pre-mixed, and the resulting mixture is
disposed on the surface of the substrate.
[00041] The following Examples are presented to further illustrate to
persons
skilled in the art how to make and use the invention. These Examples are not
intended as limitations, however, upon the scope of the invention.
EXAMPLE 1
[00042] This Example 1 evaluates the anti-microbial efficacy of coatings
ABS-
G2015, ABS-G020, and ABS G-2030, against Murine Noro Virus. Murine norovirus
(NINV) is a species of norovirus affecting mice. Norovirus is the most common
cause
of viral gastroenteritis in humans. It affects people of all ages. The virus
is transmitted
by, inter alia, aerosolization of the virus and subsequent contamination of
surfaces.
The virus affects around 267 million people and causes over 200,000 deaths
each
year; these deaths are usually in less developed countries and in the very
young,
elderly and immunosuppressed.
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
[00043] The test coupons of this Example 1 were prepared using the
Procedure
recited immediately hereinbelow.
Procedure
[00044] Put on sterile gloves.
[00045] Prepare the test coupons by wiping them first with Isopropyl
Alcohol and
allowing to dry.
[00046] Clean the test coupons with surface cleaner using a microfiber
cloth.
[00047] Hold sprayer about eight (8) inches from surface to be cleaned,
[00048] Spray on let stand for 1-3 minutes and wipe it off, if the area is
extremely
dirty allow cleaner to stand longer, or apply a second spray and wipe.
[00049] Wipe surface with a clean, damp sponge or cloth.
[00050] Allow surface to completely dry.
[00051] With gloved hands examine coupons for consistency.
[00052] Prepare a 10 volume percent solution of the selected silane in
Methanol
(Me0H) (10 ml silane in 90 ml Me0H).
[00053] Prepare Triethanolamine as a 10 volume percent solution in Me0H.
[00054] Combine the triethanol amine solution and the silane solution in a
1:1 ratio
on a stir plate at room temperature (ie-100 ml triethanolamine solution added
to 100
ml silane solution).
Si lane Application
[00055] Add the silane / triethanolamine solution from [00041] to the
applicator
container.
[00056] Fasten the Liquid Hose/Bottle cap assembly tightly on the
container.
[00057] Connect the air hose from compressor to air fitting on the spray
applicator.
[00058] Connect the liquid hose to the liquid fitting on the spray
applicator.
[00059] Plug the power cord into an appropriate receptacle. Turn on the
air
compressor.
[00060] Optimal spraying distance is at least 36 to 48 inches away from
the target
surface.
[00061] Hold the spray gun at right angles to the target surface and
spray.
11
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00062] Target surface should just barely glisten with the spray. Do not
over-
saturate the surface.
[00063] Allow target surface to dry, i.e. allow at least 90 weight percent
of the
methanol liquid carrier to evaporate to give a deposition consisting
essentially of the
selected silane and triethanolamine. The deposition onto the target surface
consists of
at least 33 volume percent of the selected silane, at least 33 volume percent
of
triethanolamine, and up to about 33 volume percent residual methanol carrier
liquid.
[00064] Rinse spray gun with distilled water prior to applying Inventors'
Titanyl-
Oxide Moieties (unless using 2 sprayers, one for each product).
Titanyl-Oxide Moieties Application.
[00065] Add an aqueous mixture of Inventors' Titanyl-Oxide Moieties to the
applicator container.
[00066] Fasten the Liquid Hose/Bottle cap assembly tightly on the
container.
[00067] Connect the air hose from compressor to air fitting on the spray
applicator.
[00068] Connect the liquid hose to the liquid fitting on the spray
applicator.
[00069] Plug the power cord into an appropriate receptacle. Turn on the
air
compressor.
[00070] Optimal spraying distance is at least 36 to 48 inches away from
the target
surface.
[00071] Hold the spray gun at right angles to the target surface and
spray.
[00072] Target surface should just barely glisten with the spray. Do not
over-
saturate the surface.
[00073] Allow target surface to dry, i.e. allow at least 90 weight percent
of the
water liquid carrier to evaporate to give a deposition consisting essentially
of
Inventors' Titanyl-Oxide Moieties. The deposition onto the target surface
consists of
at least 66 volume percent of Inventors' Titanyl-Oxide Moieties and up to
about 33
volume percent residual water carrier liquid.
[00074] Clean the spray gun with distilled water per manufactures'
specifications
after each day of use.
12
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
1000751 FIG. 4 and FIG. 5 recite anti-microbial efficacy data four (4)
hours after
inoculation of the treated test coupons. FIG. 4 includes data for ABS-G2020
and
ABS-G2030 treated Formica coupons. FIG. 5 includes data for ABS-G2020 and ABS
G-2030 treated stain less steel coupons.
[00076] RAW (mouse macrophage) host cells were prepared in 96-well trays
24
hours prior to use in testing.
[00077] On the day of testing, a stock vial of test virus, murine
norovirus, was
removed from storage at - 80 C (titer = 5 x 108 TCID 50 units per m1). An
organic
soil load (heat-inactivated fetal bovine serum) was added to obtain a final
concentration of 5%.
[00078] Control (non-coated stainless steel and formica) and coated test
carriers
[ABS-G2015 (SS); ABS-G2020 (Form); ABS-G2030 (Form); ABS-P2015 (SS)] were
placed into sterile Petri dishes (one per dish) using pre-sterilized forceps.
[00079] Viral inocula (0.010 ml) were pipette onto the center of the
control and test
carriers, and spread over a surface area of 1-in2 using a sterile, bent
pipette tip.
[00080] One set of control carriers (per surface material type) was
harvested/neutralized immediately to determine Time Zero counts by placement
into
sterile stomacher bags containing 3 ml of neutralizing solution (calf serum
supplemented with .001% Na-thiosulfate and .001% Na-thioglycollate). The bags
were stomached for 120 seconds athigh speed to release the viruses from the
carriers.
[00081] The remaining control and test carriers were held under ambient
conditions
for the duration of each of the specified study contact times of 4 hours and
24 hours
[placement distance/configuration: ¨68 inches (-1.7 m) below two full-spectrum
bulbs, inoculated side facing up towards the lights)]. All carriers were
observed to be
dried within 10 minutes of inoculation.
[00082] Upon closure of the respective contact times, the control and test
carriers
were neutralized by placement into sterile stomacher bags containing 3 ml of
neutralizing solution, followed by stomaching as previously described.
[00083] At the start and finish of each of the contact times, room
temperature,
relative humidity, and illuminance (lux) were measured and recorded.
13
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00084] Control and test carrier eluates were serially diluted (1:10) and
plated in
replicates of six onto RAW host cells prepared to the appropriate confluency.
[00085] The plates were observed every 24 to 48 hours to visualize viral
cytopathic
effects (CPE)and cytotoxicity.
[00086] Following a 9-day assay incubation period, the plates were
formally
scored.
[00087] Log 10 and percent reductions were calculated for each of the test
coating
formulations relative to the timed control virus counts (per surface type).
However,
reductions could not be computed for the 24 hour contact time due to
insufficient viral
recovery from the control carriers.
[00088] A neutralization validation was performed for each of the test
coating
formulations (except for ABS-P2015 due to a lack of carriers). One control
carrier
and one of each test carrier type were placed into stomacher bags containing 3
ml of
neutralizer, and processed as previously described. The eluate was serially
diluted,
and low titer inoculum of the test virus (-3-log10) was added to each of the
dilution
tubes per control and test carrier suspension. Aliquots (0.1 ml) of the
suspensions
were then plated in order to assess cytotoxic levels of the neutralized test
materials.
EXAMPLE 2
[00089] This Example 2 utilizes the three (3) silanes utilized in coating
formulations, namely ABS-G2015, ABS-G2020, and ABS-G2030, but without any
Titanyl-Oxide containing compounds. The method of Example 1 from Paragraph
[00044] through Paragraph [00064] relating to spray deposition of a silane
onto test
coupons was utilized in this Example 2. The method of Paragraph [00065]
through
and including Paragraph [00074] relating to spray deposition of the Titanyl-
Oxide
Moieties was not utilized in this Example 2.
[00090] FIG. 7 recites CFU/mL data for each of the three coating
formulations,
wherein each formulation did not include one or more titanium-oxide moieties.
FIG.
8 recites Log Reduction data for the three formulations evaluated, wherein
each
formulation did not include one or more titanium-oxide moieties. FIG. 9
recites
14
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
Percent Reduction data for the three formulations utilized, wherein each
formulation
did not include one or more titanium-oxide moieties.
EXAMPLE 3
[00091] This Example 3 utilizes complete formulations ABS-G2015, AB-G2020,
and ABS-G2030, where those coating formulations were disposed on stainless
steel
test coupons using the full procedure of Example 1. In one set of experiments,
the
formulations were disposed onto the test coupons using an electrostatic spray
assembly. In another set of experiments, the formulations were disposed onto
the test
coupons using a non-electrostatic spray assembly.
[00092] FIG. 10, FIG. 11, and FIG. 12 recite anti-microbial efficacy data
for the
electrostatic spray embodiments. FIG. 13, FIG. 14, and FIG. 15 recite anti-
microbial
efficacy data for the non-electrostatic spray embodiments.
EXAMPLE 4
[00093] A study was conducted at the Glendale Memorial Hospital and Health
Center in Glendale, CA (the "Glendale Memorial Hospital Study"). The Center
has a
24 bed intensive care (ICU). The study was performed between May 10 and
September 30, 2013. The Glendale Memorial Hospital Study was designed to
assess
the anti-microbial efficacy of coating composition AB S-G2015, described
hereinabove, where that coating composition was applied using the complete
method
of Example 1 herein.
[00094] In the Glendale Memorial Hospital Study, the entire ICU was
subjected to
the two step spray regime described herein to treat all surfaces in each room
including
hard surfaces (beds, tray tables, bed rail, walls, etc.) and soft surfaces
(drapes, cloth
and vinyl covered chairs, etc.). More specifically, each surface was first
electrostatically spray coated at room temperature using an aqueous
composition
formed by mixing Octadecylaminodimethyltrihydroxysilylpropyl Ammonium
Chloride (the "Silylated Quarternary Amine") at about 3.6 weight percent in
water.
[00095] After about fifteen (15) minutes after the electrostatic spray
coating using
the aqueous Silylated Quarternary Amine, each surface was then
electrostatically
coated at room temperature using the Titanyl-Oxide Moieties described
hereinabove.
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[00096] The treated surfaces were maintained at room temperature during
the spray
deposition of the aqueous Silylated Quarternary Amine, and during the spray
deposition of the Titanyl -Oxide Moieties. None of the treated surfaces were
subjected to any elevated heat treatment wherein the treated surface was
heated to a
temperature greater than about room temperature after completion of the two
step
coating regime.
[00097] Ninety-five ( 95) specific sites in the ICU were selected for
recurring
sampling at weeks 1, 2, 4, 8, and 15, after the two step spraying regime.
Those
selected sites included bed rails, bed controls, tray tables, and walls above
sinks.
Samples were also collected from the two ICU nursing stations and waiting
lobby
including countertops, phones, computer keyboards, chair armrests and end
tables. All
movable items were inconspicuously tagged and coded over the course of the
study so
that the same objects could be sampled.
[00098] Areas of 100 cm2 were sampled using a sponge stick containing
Letheen
broth (3M, St. Paul, MN) to neutralize any residual disinfectant. After
collection the
samples were immediately placed on ice packs and sent overnight to the
University of
Arizona for analysis by Professor Charles Gerba.
[00099] FIG. 1 hereto is a true and accurate copy of a first graph
provided by the
Manager, Infection Prevention, Dignity Health / Glendale Memorial Hospital &
Health Center. Exhibit 1 graphically shows the number of hospital acquired C-
difficile infections in the Glendale Memorial Hospital ICU from January 2012
through February 2014.
[000100] FIG 1 indicates that with the exception of September 2013, there were
no
hospital acquired C-difficile infections originating in the ICU during the
period May
2013 through November 2013. Thus, FIG. 1 shows that there was a single
hospital
acquired C-difficile infection originating in the ICU during the six month
period May
2013 through November 2013.
[000101] FIG. 1 further shows that, other than the six month period May 2013
through November 2013, there was no other 6 month period during the 25 months
from January 2012 through February 2014 wherein only a single hospital
acquired C-
difficile infection originated in the ICU.
16
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
[000102] All surfaces in the ICU were treated as described hereinabove during
the
first week of May 2013 as part of the Glendale Memorial Hospital Study. FIG. 2
hereto is a true and accurate copy of a second graph provided by the Manager,
Infection Prevention, Dignity Health / Glendale Memorial Hospital & Health
Center.
Exhibit 2 graphically shows the number of hospital acquired C-difficile
infections at
the Glendale Memorial Hospital (excluding ICU) from January 2012 through
February 2014.
[000103] FIG. 2 indicates that, with the exception of April 2013, there were
between
1 and 8 hospital acquired C-difficile infections every month during the 25
month
period in hospital areas outside of the ICU. During the period May 2013
through
November 2013, FIG. 2 shows that there were a total of 20 hospital acquired C-
difficile infections originating outside of the ICU at the Glendale Memorial
Hospital.
[000104] FIGs. 1 and 2 show that during the period May 2013 through November
2013, a single hospital acquired C-difficile infection originated in the ICU
at the
Glendale Memorial Hospital, and a total of 20 hospital acquired C-difficile
infections
originated outside of the ICU at the Glendale Memorial Hospital.
10001051 Clostridium difficile colitis or pseudomembranous colitis is colitis
(inflammation of the large intestine) resulting from infection with
Clostridium
difficile, a type of spore-forming bacteria. It causes an infectious diarrhea
called C.
difficile diarrhea. Latent symptoms of Clostridium difficile infection (CDI)
often
mimic some flu-like symptoms and may mimic disease flare-ups in people with
inflammatory bowel disease¨associated colitis. C. difficile releases toxins
that may
cause bloating and diarrhea, with abdominal pain, which may become severe.
[000106] C. difficile is transmitted from person to person by the fecal-oral
route.
The organism forms heat-resistant spores that are not killed by alcohol-based
hand
cleansers or routine surface cleaning. Thus, these spores survive in clinical
environments for long periods. Because of this, the bacteria may be cultured
from
almost any surface.
[000107] Clostridium difficile spores are extremely hardy, and can survive for
long
amounts of time in environments devoid of food. The spores are resistant to
drying
and heating, and also have resistance to many forms of antiseptic cleaners. C.
diff can
17
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
also survive in spore form for as long as five months. The ability of C. diff
to survive
in this resistant form poses quite a challenge for hospitals.
[000108] Because C. diff forms heat-resistant spores that are not killed by
alcohol-
based hand cleansers or routine surface cleaning, the data of FIG.s 1 and 2
demonstrate that treatment of hard surfaces and soft surface in the Glendale
Memorial
Hospital ICU with ABS-G2015 necessarily reduced the occurrence of C. diff
spores in
that ICU. The data of FIG. 2 show that other hospital departments that were
not
treated with ABS-G2015 coating composition experienced a much greater level of
hospital acquired C. diffinfections, thereby corroborating the anti-microbial
efficacy
of the coating resulting from application of ABS-G2015 against C. diff spores.
[000109] In coating formulations ABS G2015, G2020, and G2030, depending on the
stoichiometry of the mixture of triethanolamine and the organosilane, one or
polymeric species are formed on a treated surface. In certain embodiments, and
as
shown in Reaction Scheme 2, triethanolamine 9 and organosilane 1 react to form
a
linear polymer 10, wherein n is greater than or equal to 1 and less than or
equal to
about 10.
18
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
REACTION SCHEME 2
HO
R1
R1 0/ Ti2
\ \ /
7-\\
0-S1
'----OH
HO
9
R2 0-1.6 R1
1
__________________________________ N/
R1
\OH
io
[000110] In other embodiments, and as shown in Reaction Scheme 3,
triethanolamine 9 and organosilane 1 react to form a branched polymer 11.
19
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
REACTION SCHEME 3
HO = .R
R 0/ R2
\O-Si
OH
0
HO
9
R2 0+
/ x
0¨Si
r,
R
)
0
R., Si 0 ___________________________________
11
Wherein in Reaction Scheme 3, x is greater than or equal to 1 and less than or
equal to
about 10, and wherein y is greater than or equal to 1 and less than or equal
to about
10.
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
[000111] In other embodiments, and as shown in Reaction Scheme 4,
triethanolamine 9 and organosilane 1 react to form a cross-linked polymer 12.
REACTION SCHEME 4
HO
/R
R 0 R2
N
\
0-Si
OH
/0
HO
9
1 R
R- 0+
0--Si
OH-
-N
0 ____________________________________ 1,
12
21
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
Wherein in Reaction Scheme 4, x is greater than or equal to 1 and less than or
equal to
about 10, and wherein y is greater than or equal to 1 and less than or equal
to about
10, and wherein z is greater than or equal to 1 and less than or equal to
about 10.
[000112] In certain embodiments, Inventors' organosilane comprises
tetraethylorthosilicate 13. In certain embodiments and as shown in Reaction
Scheme
and depending on the stoichiometry of the starting materials 9 and 13,
Inventors'
cross-linked polymeric material 14 is formed by reaction of
tetraethylorthosilicate 13
and triethanolamine 9. Reaction Scheme 5 illustrates a single Si atom having
four (4)
different polymer chains originating therefrom. Those skilled in the art will
appreciate that Inventors' cross-linked polymer material 14 comprises a very
high
cross-link density.
22
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
REACTION SCHEME 5
0I
WO
0 0
01
13 9
V
0,H
* [ 0 01
N-_,\
L-0 ______________________________________________
s
H'-(5
,0
14
Wherein in Reaction Scheme 5, a is greater than or equal to 1 and less than or
equal to
about 10, and wherein b is greater than or equal to 1 and less than or equal
to about
10, and wherein c is greater than or equal to 1 and less than or equal to
about 10, and
wherein d is greater than or equal to 1 and less than or equal to about 10
[000113] In certain embodiments and as shown in Reaction Scheme 6 and
depending on the stoichiometry of the starting materials 15 and 13, Inventors'
cross-
23
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837 PCT/US2016/017599
linked polymeric material 16 is formed by reaction of tetraethylorthosilicate
13 and
diethanolamine 13. Reaction Scheme 6 illustrates a single Si atom having four
(4)
different polymer chains originating therefrom. Those skilled in the art will
appreciate that Inventors' cross-linked polymer material 16 comprises a very
high
cross-link density.
REACTION SCHEME 6
1
0
0
0- ,O,
N H
0
13 14
* [ H
H
lb *
0-1 1
J
1
* [ 0
H 15
Wherein in Reaction Scheme 6, a is greater than or equal to 1 and less than or
equal to
about 10, and wherein b is greater than or equal to 1 and less than or equal
to about
10, and wherein c is greater than or equal to 1 and less than or equal to
about 10, and
wherein d is greater than or equal to 1 and less than or equal to about 10.
24
SUBSTITUTE SHEET (RULE 26)
CA 02972923 2017-06-30
WO 2016/130837
PCT/US2016/017599
[000114] While the preferred embodiments of the present invention have been
illustrated in detail, it should be apparent that modifications and
adaptations to those
embodiments may occur to one skilled in the art without departing from the
scope of
the present invention.
SUBSTITUTE SHEET (RULE 26)
